Menu Menu

Guidelines update, v40.3

25 June, 2021

Version 40.3 of the Australian guidelines for the clinical care of people with COVID-19 includes the identification of several new studies on disease-modifying treatments as well as an added remark to tociluzumab and sarilumab recommendations acknowledging the release of updated results from REMAP-CAP.

These studies are currently under review and will be incorporated in a future version of the guidelines.